Hospira’s Global Quality Compliance Strategy Questioned In FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Letter citing GMP violations at an Italian manufacturing site is another black mark for the sterile generic injectables maker, which is seeking to become among the handful of early biosimilar entrants in the U.S. market.
You may also be interested in...
A top FDA compliance official warns the generic drug industry of a “revival” of data integrity fraud as a number of brand-name drugs go off patent and companies rush to be the first to file.
Pfizer’s plan to acquire Hospira is part of a turnaround trend in which Big Pharma hopes its quality will rub off on the troubled generics injectables sector. The question is: Will it work?
Agency leader expects to spend about a year developing a strategy to combat misinformation. On 5 August, the agency unveiled what appears to be an early component of the initiative – a web page titled Rumor Control, with facts about the safety and components of COVID-19 vaccines.